Switch theme
Sign up to access all valuation multiples
Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing.
2005
1.1K+
LTM Revenue $247M
LTM EBITDA -$143M
$1.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oxford Nanopore has a last 12-month revenue of $247M and a last 12-month EBITDA of -$143M.
In the most recent fiscal year, Oxford Nanopore achieved revenue of $218M and an EBITDA of -$136M.
Oxford Nanopore expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oxford Nanopore valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $256M | $218M | XXX | XXX | XXX |
| Gross Profit | $94.3M | $159M | XXX | XXX | XXX |
| Gross Margin | 37% | 73% | XXX | XXX | XXX |
| EBITDA | -$64.3M | -$136M | XXX | XXX | XXX |
| EBITDA Margin | -25% | -62% | XXX | XXX | XXX |
| Net Profit | -$216M | -$117M | XXX | XXX | XXX |
| Net Margin | -84% | -54% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Oxford Nanopore's stock price is GBP 1 (or $1).
Oxford Nanopore has current market cap of GBP 1.1B (or $1.4B), and EV of GBP 815M (or $1.0B).
See Oxford Nanopore trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.0B | $1.4B | XXX | XXX | XXX | XXX | $-0.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Oxford Nanopore has market cap of $1.4B and EV of $1.0B.
Oxford Nanopore's trades at 4.3x LTM EV/Revenue multiple, and -7.4x LTM EBITDA.
Analysts estimate Oxford Nanopore's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Oxford Nanopore and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.0B | XXX | XXX | XXX |
| EV/Revenue | 4.8x | XXX | XXX | XXX |
| EV/EBITDA | -7.7x | XXX | XXX | XXX |
| P/E | -7.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -5.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOxford Nanopore's NTM/LTM revenue growth is 25%
Oxford Nanopore's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Oxford Nanopore's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Oxford Nanopore's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Oxford Nanopore and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -15% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -62% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 112% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -37% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 92% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 61% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 153% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Genomictree | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oxford Nanopore acquired XXX companies to date.
Last acquisition by Oxford Nanopore was XXXXXXXX, XXXXX XXXXX XXXXXX . Oxford Nanopore acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Oxford Nanopore founded? | Oxford Nanopore was founded in 2005. |
| Where is Oxford Nanopore headquartered? | Oxford Nanopore is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Oxford Nanopore have? | As of today, Oxford Nanopore has 1.1K+ employees. |
| Who is the CEO of Oxford Nanopore? | Oxford Nanopore's CEO is Dr. Gurdial Sanghera. |
| Is Oxford Nanopore publicy listed? | Yes, Oxford Nanopore is a public company listed on LON. |
| What is the stock symbol of Oxford Nanopore? | Oxford Nanopore trades under ONT ticker. |
| When did Oxford Nanopore go public? | Oxford Nanopore went public in 2021. |
| Who are competitors of Oxford Nanopore? | Similar companies to Oxford Nanopore include e.g. Zomedica, AnteoTech, Proteomics International, Biohit. |
| What is the current market cap of Oxford Nanopore? | Oxford Nanopore's current market cap is $1.4B |
| What is the current revenue of Oxford Nanopore? | Oxford Nanopore's last 12-month revenue is $247M. |
| What is the current EBITDA of Oxford Nanopore? | Oxford Nanopore's last 12-month EBITDA is -$143M. |
| What is the current EV/Revenue multiple of Oxford Nanopore? | Current revenue multiple of Oxford Nanopore is 4.3x. |
| What is the current EV/EBITDA multiple of Oxford Nanopore? | Current EBITDA multiple of Oxford Nanopore is -7.4x. |
| What is the current revenue growth of Oxford Nanopore? | Oxford Nanopore revenue growth between 2023 and 2024 was -15%. |
| Is Oxford Nanopore profitable? | Yes, Oxford Nanopore is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
